Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen, Using Affy Arrays, to Assay SNPs for Merck ...

NEW YORK, Oct. 4 (GenomeWeb News) - Perlegen will provide genotyping services to Merck to find DNA variations with relevance to drug discovery, the company said today.


Under the agreement, Perlegen scientists will assay up to 675,000 SNPs in more than 1,000 DNA samples from individuals "with important clinical characteristics" provided by Merck.


Perlegen will use Affymetrix microarrays, including the GeneChip Human Mapping 500K array set. Merck will integrate the results with in-house data from molecular profiling of tissue samples.


The companies did not disclose the terms of the agreement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.